Exclusive Online Content
Alvotech & Bioventure Announce Approval of AVT02 (Adalimumab) as Simlandi in Saudi Arabia
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure….
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination With Cetuximab
SOTIO Biotech recently announced the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and….
Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy
Evaxion Biotech A/S recently announced the US FDA has granted fast track designation for the company’s personalized cancer therapy, EVX-01, in combination….
Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate Novel Oral Immune Response Modifier in Combination with KEYTRUDA
Teon Therapeutics (Teon) recently announced it has entered into the clinical trial collaboration agreement with Merck for the combination arm of Teon’s ongoing, two-armed, open-label, dose….
Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access
CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….
Lonza Completes Expansion to Solid Form Services Facility at Oregon Site
The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules….
Ethicann & Catalent Sign Development & License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments
Catalent and Ethicann Pharmaceuticals Inc. recently announced the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s….
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Pheno Therapeutics Limited. recently announced it has entered into an exclusive worldwide license agreement with UCB. The agreement grants Pheno Therapeutics access and rights to….
Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Ajinomoto Co., Inc. recently announced a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of….
Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic….
EXCLUSIVE ONLINE CONTENT
Abzena Launches Next-Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics & Bioconjugates
Abzena recently announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein….
Biolojic Design Announces Nektar Therapeutics Has Exercised its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021….
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….